ARZERRA®
(Ofatumumab)
Documentation
Patented
Approved 2009
FDA Letter
FDA Label
Full Sequence
Brief Summary
Function Type: ADCC
Target: CD20
Indication Category: Cancer
Patented
Approved 2009
FDA Letter
FDA Label
Full Sequence
Function Type: ADCC
Target: CD20
Indication Category: Cancer